Results 41 to 50 of about 399,367 (396)

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Leukemia, 2016
In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials–Newly Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates and a lower risk of progression to accelerated phase/blast crisis (AP/BC) than ...
A. Hochhaus, G. Saglio, T. Hughes, R. Larson, Dong-Kee Kim, S. Issaragrisil, P. Coutre, G. Étienne, P. Dorlhiac-Llacer, R. Clark, I. Flinn, H. Nakamae, B. Donohue, W. Deng, D. Dalal, H. Menssen, H. Kantarjian   +16 more
semanticscholar   +1 more source

MTSS1 is a critical epigenetically regulated tumor suppressor in CML [PDF]

, 2015
Chronic myeloid leukemia (CML) is driven by malignant stem cells that can persist despite therapy. We have identified Metastasis suppressor 1 (Mtss1/MIM) to be downregulated in hematopoietic stem and progenitor cells from leukemic transgenic SCLtTA/Bcr ...
Braunschweig, T., Brümmendorf, T. H., Chatain, N., Copland, M., Costa, I. G., Gusmao, E. G., Haenzelmann, S., Hamilton, A., Helgason, G.V., Herrmann, O., Holyoake, T. L., Kintsler, S., Koschmieder, S., Li, S., Merle Reher, M., Müller-Tidow, C., Schemionek, M., Schubert, C., Schwab, A.   +18 more
core   +1 more source

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.

Journal of Clinical Oncology, 2016
PURPOSE We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term efficacy and safety outcomes of patients with chronic myeloid leukemia ...
J. Cortes, G. Saglio, H. Kantarjian, M. Baccarani, J. Mayer, C. Boqué, N. Shah, C. Chuah, L. Casanova, Brigid Bradley-Garelik, G. Manos, A. Hochhaus   +11 more
semanticscholar   +1 more source

Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS)

Cancers, 2020
Tyrosine kinase inhibitors (TKIs), the treatment of choice for chronic myeloid leukemia (CML), can be associated to cardiovascular (CV) adverse events (AEs).
S. Cirmi, Asmae El Abd, L. Létinier, M. Navarra, F. Salvo   +4 more
semanticscholar   +1 more source

Evaluation of the primitive fraction by functional in vitro assays at the RNA and DNA level represents a novel tool for complementing molecular monitoring in chronic myeloid leukemia [PDF]

, 2018
Quantification of BCR-ABL1 mRNA levels in peripheral blood of chronic myeloidleukemia patients is a strong indicator of response to tyrosine-kinase inhibitors (TKI)treatment.
Bianchini, Michele, Cranco, Santiago, Custidiano, María del Rosario, Foncuberta, Cecilia, Freitas, Josefina, Gutierrez, Leandro German, Koile, Daniel Isaac, Larripa, Irene Beatriz, Moiraghi, Beatriz, Mordoh, Jose, Mosqueira, Celeste, Pavlovsky, Carolina, Pérez, Mariel Ana, Ruiz, María Sol, Sanchez, María Belén, Sánchez Ávalos, Julio César Américo, Ventriglia, Verónica, Yankilevich, Patricio   +17 more
core   +1 more source

Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia [PDF]

, 2001
Chronic myeloid leukemia (CML) is characterized by formation of the BCR-ABL fusion gene, usually as a consequence of the Philadelphia (Ph) translocation between chromosomes 9 and 22.
Bench, AJ, Campbell, LJ, Grace, C, Green, AR, Huntly, BJP, Nacheva, EP, Prince, HM, Reid, AG, Shepherd, P, Szer, J, Telford, N, Turner, P   +11 more
core   +1 more source

Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature

Journal of Medical Case Reports, 2018
Background Chronic lymphocytic leukemia and chronic myeloid leukemia are the most common types of adult leukemia. However, it is rare for the same patient to suffer from both.
Khadega A. Abuelgasim, Hinna Rehan, Maha Alsubaie, Nasser Al Atwi, Mohammed Al Balwi, Saeed Alshieban, Areej Almughairi   +6 more
doaj   +1 more source

Chronic Myeloid Leukemia in 2007 [PDF]

Journal of Managed Care Pharmacy, 2007
Chronic myeloid leukemia (CML), a hematopoietic stem cell cancer representing 15-20% of adult leukemias, is discussed. Epidemiology, staging biology, and monitoring techniques are reviewed.CML is a myeloproliferative disorder that affects all lineages of hematopoiesis.
openaire   +5 more sources

Uptake of synthetic low density lipoprotein by leukemic stem cells — a potential stem cell targeted drug delivery strategy [PDF]

, 2010
Chronic Myeloid Leukemia (CML) stem/progenitor cells, which over-express Bcr-Abl, respond to imatinib by a reversible block in proliferation without significant apoptosis.
Alison M. Michie, Baillie, Bellodi, Bhatia, Bocchia, Brown, Claire Crossan, Collins, Copland, Davies, Deckelbaum, Dirks, Firestone, Gal, Gavin W. Halbert, Ghalaut, Graham, Halbert, Hamilton, Hamilton, Hatziieremia, Hayavi, Hayavi, Heather G. Jørgensen, Ho, Hochhaus, Holyoake, Hughes, Jordanides, Jorgensen, Jorgensen, Kramer, Linda Scobie, Moira A. Elliott, Nikanjam, Nikanjam, Owens, Peixun Zhou, Rousselot, Sophia Hatziieremia, Stingl, Tatidis, Tessa L. Holyoake, Vitols, Weisberg, White, White, WilsonRawls   +47 more
core   +1 more source

Occurrence of chronic lymphocytic leukemia in patients with chronic myelogenous leukemia

Indian Journal of Pathology and Microbiology, 2013
Chronic lymphocytic leukemia (CLL) is the most common leukemia of adults in the western world and constitutes about 33% of all leukemia′s. The incidence of CLL increases with age and are more common in older population.
Pritish K Bhattacharyya
doaj   +1 more source